-+ 0.00%
-+ 0.00%
-+ 0.00%

Active Biotech Collaborates with US Medical Institution to Advance Myelofibrosis Treatment Development

MT Newswires·08/18/2026 05:54:45
Listen to the news
05:54 AM EDT, 08/18/2026 (MT Newswires) -- Active Biotech (ACTI.ST) entered into a collaboration agreement with a US medical institution to advance the development of its clinical drug candidate tasquinimod for myelofibrosis, a rare type of blood cancer. The biotechnology company will work with the Icahn School of Medicine at Mount Sinai in New York, US, to conduct preclinical studies aimed at further evaluating tasquinimod's potential as a monotherapy and in combination with other treatments, according to a Tuesday release. The collaboration will also support the expansion of Active Biotech's ongoing US clinical program for tasquinimod through the Myeloproliferative Neoplasms Research Consortium.